🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk
NCT06670677Hypertension, Cardiovascular Risk, Blood Pressure Check (Hypertension Screening)
Aktiia SA
Observational
15,000
London
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
Eidos Therapeutics, a BridgeBio company
Phase 3
587
London
2025-05-12
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
425
Bristol, Bury, Llanrhystud, London, Stockport
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
Belfast, London, Middlesex, Sunderland
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
London, Liverpool, Sutton, Manchester
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Cambridge, Leeds, London, Manchester
2025-05-06
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
BioNTech SE
Phase 1/2
594
Bristol, Leeds, Liverpool, London, Manchester, Preston
2025-05-02
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2
59
London
2025-05-01
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
72
Glasgow, London, Southampton
2025-05-01
By invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07055607Obesity
Novo Nordisk A/S
Observational
1,250
West Bromwich, Barnsley, Hull, London, Luton, Tooting
2025-05-01
Not yet open
Non-invasive Detection of Coronary Artery Stenosis
NCT06750016Coronary Arterial Disease (CAD)
Nilocas
Observational
20
London
2025-05
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals
Phase 3
340
Chichester, London, Manchester, Tyne and Wear
2025-04-30
Active, closed
Pediatric Expansion Study of the Sentio System
NCT06976086Hearing Loss, Conductive, Hearing Loss, Mixed, Single Sided Deafness
Oticon Medical
Not applicable
50
Birmingham, London
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Glasgow, London
2025-04-29
Active, closed
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
NCT06883240Von Willebrand Disease, Type 3
Hoffmann-La Roche
Observational
44
London, Manchester
2025-04-29
By invitation
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT06926621Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated
Phase 2
44
Glasgow, London, Sheffield
2025-04-28
Recruiting
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
NCT06836609Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals
Phase 1/2
132
London, Harrow
2025-04-28
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
London, Birmingham, Guildford, Manchester
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
288
Torquay, London, Dundee
2025-04-24
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
AbbVie
Phase 2
390
London, Oxford, Sutton, Manchester
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Active, closed
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 1/2
15
Sheffield, London
2025-04-22
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
Vanda Pharmaceuticals
Phase 3
420
Great Yarmouth, Leicester, Liverpool, London, Sheffield
2025-04-21
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Cottingham, Birmingham, Cambridge, Leicester, London
2025-04-17
Active, closed
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
NCT06712563Pulmonary Disease, Chronic Obstructive
AstraZeneca
Observational
2,000
London
2025-04-17
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
Neurocrine Biosciences
Phase 3
850
Southampton, Sheffield, London, Manchester
2025-04-16
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
Merck Sharp & Dohme LLC
Phase 2
440
London
2025-04-16
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
752
Dudley, Harrow, Kings Lynn, London, Reading, Salford, Southampton, Wakefield
2025-04-15
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC
Phase 1/2
605
Brighton, Fulham, Sutton, London, Manchester
2025-04-15
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC
Phase 2
594
Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford
2025-04-11
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
250
Aberdeen, Birmingham, Bournemouth, London, Southampton
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
NCT06846554Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd
Phase 2
48
London, Bath, Cambridge, Clydebank, Sheffield
2025-04-09
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
869
Plymouth, Torquay, London
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
London, Sutton
2025-04-07
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
Basildon, Bristol, Leeds, Leicester, London
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Disc Medicine, Inc
Phase 3
183
London, Dundee, Salford
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
London
2025-04-03
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Enfield, Glasgow, High Wycombe, London, Manchester, Metropolitan Borough of Wirral, Preston, Rochdale
2025-04-02
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
Pfizer
Phase 3
674
East Sussex, Dundee, London, Worthing
2025-04-01
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
London, Manchester
2025-03-31
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
Daiichi Sankyo
Phase 3
510
Belfast, Dundee, London, Manchester, Plymouth
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.
Phase 3
157
Plymouth, Hampstead, Bristol, Cambridge, Frimley, London
2025-03-20
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Cambridge, London, Manchester, Oxford, Sheffield
2025-03-19
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
2025-03-17
Recruiting
Post-Market Data Collection to Evaluate the Performance of the Synergy Disc®
NCT06383962Cervical Degenerative Disc Disease
Synergy Spine Solutions
Observational
50
Birmingham, London
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals
Phase 2
126
Cambridge, Glasgow, London, Manchester
2025-03-13
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
Celgene
Phase 3
960
Glasgow, Northwood, London, Manchester
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Cambridge, London, Manchester, Metropolitan Borough of Wirral
2025-03-12
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
Vir Biotechnology, Inc.
Phase 3
124
London, Manchester, Nottingham
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield
2025-03-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
Glasgow, London, Torquay
2025-03-11
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
London, Coventry, Bradford, Harlow, Oxford, Stoke-on-Trent, Wolverhampton
2025-03-10
Recruiting
Inari VISION Registry
NCT06600542Pulmonary Embolism
Inari Medical
Observational
1,000
Bristol, Glasgow, London, Newcastle, Swindon
2025-03-07
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Birmingham, London
2025-03-07
Active, closed
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987APOL1-Mediated Kidney Disease
AstraZeneca
Phase 2
57
Birmingham, Leicester, Liverpool, London, Manchester
2025-03-05
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Birmingham, Bournemouth, Glasgow, Headington, London, Metropolitan Borough of Wirral, Plymouth
2025-03-05
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
Tyra Biosciences, Inc
Phase 2
92
London, Sheffield
2025-03-04
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
GlaxoSmithKline
Phase 1/2
305
Glasgow, London
2025-03-04
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
BicycleTx Limited
Phase 2
66
London
2025-03-03
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
BioNTech SE
Phase 2
60
Cardiff, Leeds, London, Manchester
2025-03-03
Recruiting
Vision Baby : The Measurement of Vital Signs in Neonates by Lifelight® Software in Comparison to the Standard of Care
NCT07799870Neonatal Diseases and Abnormalities, Vital Sign Monitoring
Xim Limited
Observational
256
London
2025-03-01
Not yet open
Multivitamin Intervention and Cognitive Function
NCT06795789Healthy Adult, Cognitive Measures
Braincare Limited
Not applicable
30
London
2025-03-01
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Cambridge, Coventry, Dundee, London, Manchester, Sutton
2025-03-01
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
NCT06939374Coronary Arterial Disease (CAD), Plaque, Vulnerable Plaque, Cryotherapy
Cryotherapeutics SA
Not applicable
30
London
2025-03-01
Recruiting
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
NCT06764316Hepatocellular Carcinoma
Bayer
Phase 1
148
London, Glasgow, Sutton
2025-02-28
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
Incyte Corporation
Phase 3
600
Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford
2025-02-28
Recruiting
Tensi+ European Registry
NCT07205445Overactive Bladder
Stimuli Technology
Observational
500
Bristol, Cambridge, London
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester
2025-02-27
Active, closed
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
NCT06717126Uveal Melanoma, Ocular Melanoma
iOnctura
Phase 2
85
Northwood, Bebington, Glasgow, London, Southampton
2025-02-27
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 1/2
327
London, Liverpool, Manchester
2025-02-27
Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394Breast Neoplasms, Breast Cancer
Merck Sharp & Dohme LLC
Phase 1/2
81
London, Glasgow
2025-02-26
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2
200
Birmingham, London
2025-02-25
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
Amgen
Phase 3
844
Portsmouth, Leeds, London
2025-02-25
Active, closed
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017Alpha 1-Antitrypsin Deficiency
BioMarin Pharmaceutical
Phase 1
6
Edinburgh, London, Southampton
2025-02-21
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
London
2025-02-20
Recruiting
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment
NCT06598163Mild Cognitive Impairment
SharpTx
Not applicable
170
Exeter, Preston, Oxford, Taunton, London
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH
Phase 2
56
Leeds, London, Manchester
2025-02-19
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
Gilead Sciences
Phase 2
39
London
2025-02-18
Recruiting
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782Neoplasms, Colon
GlaxoSmithKline
Phase 2
120
Glasgow, Leeds West Yorkshire, London, Sutton
2025-02-18
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
Novo Nordisk A/S
Phase 3
510
Cambridge, London
2025-02-17
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
AbbVie
Phase 3
420
London, Gillingham, Aberdeen, Stockport
2025-02-13
Recruiting
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
NCT06523400Myotonic Dystrophy
Lupin Ltd.
Phase 3
176
London
2025-02-13
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 3
324
Cardiff, Newcastle upon Tyne, Glasgow, London
2025-02-12
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
Novo Nordisk A/S
Phase 3
400
Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton
2025-02-10
Recruiting
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NCT06533098Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC
Phase 3
50
Birmingham, Liverpool, London, Oxford
2025-02-10
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
AbbVie
Phase 3
468
Poole, Brighton, London, Thetford, Oxford
2025-02-10
Rows per page Showing 501–600 of 2005
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=6

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.